Blog

Navneet Singh: The importance of predictive biomarker testing in all adenocarcinoma/non-squamous NSCLC

Navneet Majhail/X

Nov 26, 2024, 11:27

Navneet Singh: The importance of predictive biomarker testing in all adenocarcinoma/non-squamous NSCLC

Navneet Singh, Thoracic Medical Oncologist and a Professor at PGIMER, shared a post by IASLC on LinkedIn, adding:

“Prevalence in South Asia of EGFR mutations is approximately 30% and of ALK fusions/rearrangements approximately 10% – highlighting the importance of predictive biomarker testing in all adenocarcinoma / non-squamous NSCLC and other histological subtypes whenever clinically indicated. Targeted therapies have a significant impact on clinical outcomes when offered to patients selected based on results of biomarker testing.”

Quoting IASLC‘s post:

“Targeted therapies, designed to treat specific genetic mutations like EGFR, ALK, and ROS1, are offering improved outcomes for patients, especially those with non-small cell lung cancer. This approach tailors treatment to each individual’s genetic profile, maximizing effectiveness. Let’s continue supporting personalized cancer care!”

Navneet Singh

More posts featuring Navneet Singh and IASLC.

Dr. Navneet Singh, a thoracic medical oncologist and a professor at PGIMER, Chandigarh, specializes in non-small cell lung cancer (NSCLC) treatment, focusing on targeted therapies and immunotherapy. He leads PGIMER’s thoracic oncology group, which won the Lung Cancer Care Team Award at the 2019 WCLC. Dr. Singh received the prestigious Clifton Mountain Lectureship Award in 2023. With over 200 publications, he’s contributed significantly to the field, serving on various committees and earning ASCO’s IDEA and FASCO awards.